Legal & General Group
PMVP icon

Legal & General Group’s PMV Pharmaceuticals PMVP Stock Holding History

Legal & General Group’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,468
Closed -$5.9K – 3488
2024
Q1 		$5.9K Hold
3,468
– – ﹤0.01% 3283
2023
Q4 		$10.8K Hold
3,468
– – ﹤0.01% 3223
2023
Q3 		$21.3K Hold
3,468
– – ﹤0.01% 2997
2023
Q2 		$21.7K Sell
3,468
-972
-22% -$5.09K ﹤0.01% 3086
2023
Q1 		$21.2K Sell
4,440
-4,041
-48% -$28.4K ﹤0.01% 3053
2022
Q4 		$73.8K Hold
8,481
– – ﹤0.01% 2876
2022
Q3 		$101K Buy
8,481
+359
+4% +$5.19K ﹤0.01% 2822
2022
Q2 		$116K Buy
8,122
+1,055
+15% +$15.4K ﹤0.01% 2815
2022
Q1 		$147K Sell
7,067
-9
-0.1% -$159 ﹤0.01% 2773
2021
Q4 		$164K Buy
7,076
+60
+0.9% +$1.45K ﹤0.01% 2785
2021
Q3 		$209K Buy
7,016
+3,890
+124% +$124K ﹤0.01% 2678
2021
Q2 		$107K Buy
3,126
+1,697
+119% +$56.7K ﹤0.01% 2710
2021
Q1 		$47K Sell
1,429
-45
-3% -$1.77K ﹤0.01% 2830
2020
Q4 		$90K Sell
1,474
-44,826
-97% -$1.76M ﹤0.01% 2615
2020
Q3 		$1.73M Buy
+46,300
New +$1.7M ﹤0.01% 1827

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Legal & General Group's PMVP Position: Q2 2024 in Review

Legal & General Group sold out of PMV Pharmaceuticals (PMVP) in Q2 2024, closing a stake of 3,468 shares — an estimated $5.9K sold.

Legal & General Group first reported a position in PMVP in Q3 2020 and held it in 15 quarters. The position peaked at $1.73M in Q3 2020. 93 funds tracked by Wall St. Rank hold PMVP as of Q2 2024.

  • Legal & General Group reported no remaining PMV Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Legal & General Group sold 3,468 PMV Pharmaceuticals shares in Q2 2024, an estimated $5.9K.
  • Legal & General Group first reported a position in PMV Pharmaceuticals in Q3 2020 and held it in 15 quarters.
  • Legal & General Group's PMV Pharmaceuticals position peaked at $1.73M in Q3 2020.
  • 93 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2024.

Based on Legal & General Group's 13F filing for Q2 2024, filed 14 Aug 2024.